0000000000141586

AUTHOR

Genoveffa Pizza

showing 3 related works from this author

Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives

2017

urpose Everolimus has been shown to be effective for advanced pancreatic neuroendocrine tumours (pNETs), but its positioning in the therapeutic algorithm for pNETs is matter of debate. Methods With the aim to shed light on this point, we performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies, and the recommendations of international guidelines. In addition, we performed an extensive search on the Clinical Trial Registries databases worldwide, to gather information on the ongoing clinical trials related to this specific topic. Results We identified eight retrospective published studies, two prospective published studies…

0301 basic medicinemTOR inhibitorsCancer Researchmedicine.medical_specialtyPathologymTOR inhibitorEverolimus; mTOR inhibitors; Neuroendocrine tumours; Therapy; Antineoplastic Agents; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Oncology; Cancer ResearchTherapeutic algorithmEverolimus; mTOR inhibitors; neuroendocrine tumours; therapy; antineoplastic agents; everolimus; humans; neuroendocrine tumours; pancreatic neoplasms; oncology; cancer researchEndocrine SyndromeNeuroendocrine tumorsAntineoplastic Agent03 medical and health sciences0302 clinical medicineFirst line therapyNeuroendocrine tumourantineoplastic agentsmedicinehumansIntensive care medicinetherapyEverolimusbusiness.industryPancreatic Neoplasmpancreatic neoplasmsGeneral Medicineeverolimusmedicine.diseaseDiscovery and development of mTOR inhibitorsClinical trialEverolimuNeuroendocrine Tumors030104 developmental biologyOncology030220 oncology & carcinogenesisneuroendocrine tumoursNeuroendocrine TumorbusinessEverolimus; mTOR inhibitors; Neuroendocrine tumours; Therapy; Antineoplastic Agents; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic NeoplasmsHumanmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct

From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?

2020

AbstractGut microbiota is represented by different microorganisms that colonize the intestinal tract, mostly the large intestine, such as bacteria, fungi, archaea and viruses. The gut microbial balance has a key role in several functions. It modulates the host’s metabolism, maintains the gut barrier integrity, participates in the xenobiotics and drug metabolism, and acts as protection against gastro-intestinal pathogens through the host’s immune system modulation. The impaired gut microbiota, called dysbiosis, may be the result of an imbalance in this equilibrium and is linked with different diseases, including cancer. While most of the studies have focused on the association between microb…

Endocrinology Diabetes and MetabolismTumor microenvironment.BiologyGut floraNeuroendocrine tumorsmedicine.disease_causedigestive systemArticle03 medical and health sciences0302 clinical medicineEndocrinologyImmune systemNeuroendocrine tumorGastro-medicineHumansCytokine030304 developmental biologyGastrointestinal NeoplasmsInflammation0303 health sciencesTumor microenvironmentMicrobiotadigestive oral and skin physiologymedicine.diseasebiology.organism_classificationCytokines; Inflammation; Microbiota; Neuroendocrine tumors; Tumor microenvironmentGastrointestinal MicrobiomeTumor microenvironment030220 oncology & carcinogenesisImmunologyDysbiosisCytokinesNeuroendocrine tumorsCarcinogenesisDysbiosisDrug metabolism
researchProduct

The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?

2018

Purpose: Analyze the role of somatostatin analogues (SSAs) in the treatment of sporadic and MEN1-related gastrinomas, trying to define whether recent trials have changed the landscape of gastrinoma therapy. Methods: We evaluate the rationale of SSA use in the treatment of gastrinomas, summarize the current literature concerning the effect of SSAs on the control of Zollinger-Ellison syndrome (ZES) and gastrinomas tumor progression and discuss their role in the most recent guidelines. Results: The medical treatment of gastrinoma and related ZES is aimed at controlling acid hypersecretion and tumor progression, in inoperable patients. The use of proton pump inhibitors (PPIs) to control the syn…

Oncologymedicine.medical_specialtyProton Pump InhibitorAntineoplastic Agents HormonalEndocrinology Diabetes and MetabolismGastrinoma; neuroendocrine tumours; somatostatin; somatostatin analogues; endocrinology; diabetes and metabolism; endocrinologyNeuroendocrine tumorssomatostatinOctreotideSomatostatin analogueSettore MED/13 - EndocrinologiaZollinger-Ellison Syndrome03 medical and health sciencesendocrinology0302 clinical medicineInternal medicineNeuroendocrine tumourmedicineHumansProgression-free survivaldiabetes and metabolismGastrinomaMedical treatmentsomatostatin analoguesbusiness.industryDisease progressionPancreatic NeoplasmProton Pump Inhibitorsmedicine.diseasedigestive system diseasesZollinger-Ellison syndromePancreatic NeoplasmsEndocrinologySomatostatinTreatment OutcomeTumor progression030220 oncology & carcinogenesisGastrinoma030211 gastroenterology & hepatologyneuroendocrine tumoursbusinessHuman
researchProduct